Fundraising FoxViscient Biosciences
San Diego, US · Founded 2016 · 4 known investors
Find your way into Viscient Biosciences
Sign up to see every warm intro you have to Viscient Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Viscient Biosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Viscient Biosciences develops drugs by studying human 3D tissue models combined with multi-omics analysis to understand disease mechanisms. The company initially focuses on non-alcoholic steatohepatitis (NASH) drug discovery.
Founders & leadership
Viscient Biosciences was founded in 2016 by Keith Murphy.
KM
Keith MurphyCEO and FounderKeith Murphy spent a decade at Amgen in operations leadership for major franchises, then co-founded and led Organovo for ten years, taking it public and to a $1B+ valuation before overseeing the sale of its IBD program to Eli Lilly. He subsequently founded VivoSim to apply 3D human cell models and AI to improve drug safety assessment, and currently serves as an executive officer at Viscient Bio, which is advancing MASH drug candidates using proprietary human tissue models.
Investors · 4
Reported raises · per SEC filings
Form D private placements$1M disclosed across 1 round · 2021
▶$1MraisedSep 2021 · 12 investors · BiotechnologyRule 506(b)
▶$1MraisedSep 2021 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Keith MurphyExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $1M
- Sales commissions
- $100K
- Placement agents
- Jamie Polak, Adam Stern, David Reimer, Ronald Lazar
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Viscient Biosciences do?
- Viscient Biosciences develops drugs by studying human 3D tissue models combined with multi-omics analysis to understand disease mechanisms. The company initially focuses on non-alcoholic steatohepatitis (NASH) drug discovery.
- Who founded Viscient Biosciences?
- Viscient Biosciences was founded by Keith Murphy in 2016.
- Who are Viscient Biosciences's investors?
- Viscient Biosciences's investors include Harmonix Fund, Methuselah Foundation, Methuselah Funds, Thynk Capital.
- How much funding has Viscient Biosciences raised?
- Viscient Biosciences has disclosed $1M raised across 1 round.
- Where is Viscient Biosciences headquartered?
- Viscient Biosciences is headquartered in San Diego, US.